Open | - |
Close | - |
Volume / Avg. | 3.000 / 159.987K |
Day Range | - - - |
52 Wk Range | 2.120 - 4.139 |
Market Cap | $193.038M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 30 |
Short Interest | 6.21% |
Days to Cover | 24.21 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Ovid Therapeutics (NASDAQ: OVID) through any online brokerage.
Other companies in Ovid Therapeutics’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Graphite Bio (NASDAQ:GRPH), Innate Pharma (NASDAQ:IPHA), Atossa Therapeutics (NASDAQ:ATOS) and FibroGen (NASDAQ:FGEN).
The latest price target for Ovid Therapeutics (NASDAQ: OVID) was reported by BTIG on Thursday, December 21, 2023. The analyst firm set a price target for 11.00 expecting OVID to rise to within 12 months (a possible 302.93% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Ovid Therapeutics (NASDAQ: OVID) is $2.73 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Ovid Therapeutics.
Ovid Therapeutics’s Q1 earnings are confirmed for Friday, May 3, 2024.
There is no upcoming split for Ovid Therapeutics.
Ovid Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.